시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 대상포진 후 신경통(PHN) 시장 보고서(2025년)
Postherpetic Neuralgia (PHN) Global Market Report 2025
상품코드 : 1769715
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,310,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,121,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,932,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

대상포진 후 신경통(PHN) 시장 규모는 향후 수년간 강력한 성장이 전망될 예정입니다. 성장을 견인하는 주요인으로서는 항바이러스 요법이나 백신의 사용 확대, 만성 통증 질환의 급증, 첨단 약물 전달 시스템의 도입 확대, 임상 검사나 연구 개발에의 투자 증가, 새로운 치료 선택에 대한 규제 당국의 승인 증가 등을 들 수 있습니다. 향후 몇 년간에 예상되는 새로운 동향으로서는 신경장애성 통증 치료 연구의 진전, 드러그 딜리버리 메커니즘의 혁신, 기술 주도형 진단 솔루션의 이용, 임상 연구에 있어서의 인공지능의 응용, 비오피오이드 통증 완화 방법의 진화 등이 포함됩니다.

만성 통증 질환의 유병률 증가는 향후 수년간 대상 포진 후 신경통(PHN) 시장의 성장을 가속할 것으로 예측됩니다. 혹은 반복적인 불쾌감을 가리키며, 종종 질병이나 부상의 정상적인 경과를 넘어 지속되며, 일상 기능과 삶의 질에 큰 영향을 미칩니다. 신경 장애와 같은 퇴행성 질환에 걸리기 쉽고, 그 결과 통증이 계속되는 경우가 많기 때문입니다. Office for Health Improvement and Disparities가 발표한 보고서에 따르면 2023년에는 16세 이상의 약 18.4%가 장기적인 근골격계(MSK) 질환을 가지고 있다고 보고했으며, 2022년의 17.6%에서 증가했습니다.

대상포진 후 신경통(PHN) 시장 진출기업들은 제품 라인업을 확대하고 경쟁 우위를 확보하고 보다 효과적이고 내약한 치료에 대한 큰 미충족 요구에 대응하기 위해 규제 당국의 승인 취득에 점점 주력하고 있습니다. 약사 승인이란, 의료 당국으로부터 정식으로 허가된 것으로, 특정의 의료 적응증에 대해서 약이나 치료법의 합법적인 판매·투여를 허가하는 것입니다. 예를 들어 2023년 2월 인도 제약회사인 Zydus Lifesciences Ltd.는 미국 식품의약국(FDA)으로부터 하루 1회 복용 Gabapentin 정제 300mg과 600mg의 제네릭 의약품을 제조 및 판매하는 최종 승인을 취득했습니다. 이 Gabapentin 정제는 수두와 대상 포진 바이러스의 재 활성화에 의한 신경 장애로 인한 신경 병성 통증의 일종인 PHN의 치료에 사용됩니다. 일반적으로 첫날은 300mg부터 시작하여 2일째에 600mg(300mg을 1일 2회), 3일째에 900mg(300mg를 1일 3회)까지 증량하고, 환자의 요구에 따라 최대 1일 1,800mg(600mg를 1일 3회)까지 점증합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나연과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

제36장 부록

SHW
영문 목차

영문목차

Postherpetic neuralgia (PHN) is a chronic nerve pain disorder that arises as a complication after an episode of herpes zoster (shingles). It is marked by ongoing, often intense pain in the area previously affected by the shingles rash, which can persist for months or even years after the skin has healed. PHN stems from nerve injury caused by the reactivation of the varicella-zoster virus and represents the most frequent complication of shingles, particularly among older individuals.

The primary treatment types for postherpetic neuralgia (PHN) include patches, medications, and opioids. Patches are transdermal drug delivery systems applied directly to the skin to ensure a consistent release of the drug into the bloodstream. These treatments are distributed via hospital pharmacies, retail pharmacies, and online platforms, and are utilized by hospitals, clinics, ambulatory surgical centers, and other healthcare providers.

The postherpetic neuralgia (PHN) market size has grown strongly in recent years. It will grow from $0.72 billion in 2024 to $0.77 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The factors contributing to historical growth include a higher incidence of herpes zoster infections, an expanding elderly population, enhanced awareness among both patients and healthcare providers, rising demand for effective treatments targeting neuropathic pain, and increased healthcare spending.

The postherpetic neuralgia (PHN) market size is expected to see strong growth in the next few years. It will grow to $0.99 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. Key drivers for future growth include the expanded usage of antiviral therapies and vaccines, a surge in chronic pain conditions, greater implementation of advanced drug delivery systems, increased investment in clinical trials and R&D, and a rise in regulatory approvals for new treatment options. Emerging trends expected in the coming years involve progress in neuropathic pain treatment research, innovation in drug delivery mechanisms, the use of tech-driven diagnostic solutions, the application of artificial intelligence in clinical studies, and the evolution of non-opioid pain relief methods.

The increasing prevalence of chronic pain conditions is expected to drive the growth of the postherpetic neuralgia (PHN) market in the coming years. Chronic pain refers to persistent or recurring discomfort that lasts more than three months, often continuing beyond the normal course of an illness or injury and significantly affecting daily functioning and quality of life. This rising prevalence is largely attributed to the aging population, as older adults are more susceptible to degenerative diseases such as arthritis and neuropathy, which often result in ongoing pain. Postherpetic neuralgia serves as a valuable model for chronic pain research, helping to better understand nerve-related pain mechanisms and assess long-term treatment strategies. For example, in January 2024, a report published by the Office for Health Improvement and Disparities, a UK-based government department, indicated that approximately 18.4% of individuals aged 16 and above reported having a long-term musculoskeletal (MSK) condition in 2023, up from 17.6% in 2022. As a result, the growing incidence of chronic pain conditions is contributing to the expansion of the PHN market.

Companies involved in the postherpetic neuralgia (PHN) market are increasingly focusing on securing regulatory approvals to broaden their product offerings, gain a competitive edge, and address the substantial unmet need for more effective and better-tolerated treatments. Regulatory approvals refer to official permissions granted by health authorities, allowing a medication or therapy to be legally marketed and administered for a specific medical indication. For instance, in February 2023, Zydus Lifesciences Ltd., an India-based pharmaceutical company, received final approval from the United States Food and Drug Administration to produce and market once-daily generic Gabapentin Tablets in 300 mg and 600 mg doses, indicated for managing postherpetic neuralgia (PHN). These gabapentin tablets are used to treat PHN, a type of neuropathic pain caused by nerve damage due to reactivation of the varicella-zoster virus. Typical dosing begins at 300 mg on the first day, increases to 600 mg (300 mg twice daily) on the second day, and 900 mg (300 mg three times daily) on the third day, with potential titration up to a maximum of 1800 mg per day (600 mg three times daily) based on patient needs.

In September 2023, Adalvo Limited, a Malta-based pharmaceutical company specializing in service-based pharmaceutical partnerships, teamed up with Lotus Pharmaceutical Co. Ltd. to introduce Gabapentin ER tablets in South Korea. This strategic collaboration is intended to improve patient access to innovative and effective therapies by launching Gabapentin ER in the South Korean market, thereby reinforcing the companies' presence in the neurology sector and expanding their portfolios with high-value pharmaceutical offerings. Lotus Pharmaceutical Co., Ltd. is a Taiwan-based pharmaceutical firm that manufactures medications, including those for the treatment of postherpetic neuralgia (PHN).

Major players in the postherpetic neuralgia (phn) market are Pfizer Inc., Merck & Co. Inc., Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Mylan N.V., Mallinckrodt plc, Merz Therapeutics GmbH, Acorda Therapeutics Inc., Scilex Holding Company, Elorac Inc., Lexicon Pharmaceuticals Inc., Oxford Cannabinoid Technologies Holdings plc, Teikoku Pharma USA Inc., Acasti Pharma Inc., Flexion Therapeutics Inc., Haisco Pharmaceutical Group Co. Ltd., Shanghai SIMR Biotechnology Co. Ltd.

North America was the largest region in the postherpetic neuralgia (PHN) market in 2024. The regions covered in postherpetic neuralgia (PHN) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the postherpetic neuralgia (PHN) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The postherpetic neuralgia (PHN) market includes revenues earned by entities by providing services such as medical consultation, pain management services, topical treatment application, physical therapy and nerve block or injections. The market value includes the value of related goods sold by the service provider or included within the service offering. The postherpetic neuralgia (PHN) market consists of sales of anticonvulsants, amitriptyline, tramadol, oxycodone, and nortriptyline. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Postherpetic Neuralgia (PHN) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on postherpetic neuralgia (phn) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for postherpetic neuralgia (phn) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The postherpetic neuralgia (phn) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Postherpetic Neuralgia (PHN) Market Characteristics

3. Postherpetic Neuralgia (PHN) Market Trends And Strategies

4. Postherpetic Neuralgia (PHN) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Postherpetic Neuralgia (PHN) Growth Analysis And Strategic Analysis Framework

6. Postherpetic Neuralgia (PHN) Market Segmentation

7. Postherpetic Neuralgia (PHN) Market Regional And Country Analysis

8. Asia-Pacific Postherpetic Neuralgia (PHN) Market

9. China Postherpetic Neuralgia (PHN) Market

10. India Postherpetic Neuralgia (PHN) Market

11. Japan Postherpetic Neuralgia (PHN) Market

12. Australia Postherpetic Neuralgia (PHN) Market

13. Indonesia Postherpetic Neuralgia (PHN) Market

14. South Korea Postherpetic Neuralgia (PHN) Market

15. Western Europe Postherpetic Neuralgia (PHN) Market

16. UK Postherpetic Neuralgia (PHN) Market

17. Germany Postherpetic Neuralgia (PHN) Market

18. France Postherpetic Neuralgia (PHN) Market

19. Italy Postherpetic Neuralgia (PHN) Market

20. Spain Postherpetic Neuralgia (PHN) Market

21. Eastern Europe Postherpetic Neuralgia (PHN) Market

22. Russia Postherpetic Neuralgia (PHN) Market

23. North America Postherpetic Neuralgia (PHN) Market

24. USA Postherpetic Neuralgia (PHN) Market

25. Canada Postherpetic Neuralgia (PHN) Market

26. South America Postherpetic Neuralgia (PHN) Market

27. Brazil Postherpetic Neuralgia (PHN) Market

28. Middle East Postherpetic Neuralgia (PHN) Market

29. Africa Postherpetic Neuralgia (PHN) Market

30. Postherpetic Neuralgia (PHN) Market Competitive Landscape And Company Profiles

31. Postherpetic Neuralgia (PHN) Market Other Major And Innovative Companies

32. Global Postherpetic Neuralgia (PHN) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Postherpetic Neuralgia (PHN) Market

34. Recent Developments In The Postherpetic Neuralgia (PHN) Market

35. Postherpetic Neuralgia (PHN) Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기